Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 20, 2021


BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)





(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)


Identification No.)


54 Wilton Road, 2nd Floor

Westport, Connecticut



(Address of principal executive offices)


(Zip Code)


(203) 409-5444

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol(s)


Name of exchange on which registered

Common Stock, par value $0.001 per share




The NASDAQ Capital Market  


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On September 20, 2021, the board of directors (the “Board”) of BioSig Technologies, Inc. (the “Company”) appointed James J. Barry, Ph.D. as a director of the Company, effective as of the same date, to fill a vacancy as a result of the increase in the size of the Board from six to seven persons, effective as of the same date, to serve for a term expiring at the 2022 annual meeting of the Company’s stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal. For Dr. Barry’s service on the Board, Dr. Barry will receive compensation consistent with market practices of similarly situated companies that is consistent with the Company’s non-employee director compensation policy as may be then in effect. In addition, Dr. Barry was granted 50,000 restricted stock units, 50% of which vested immediately upon Dr. Barry’s acceptance of the Board’s offer of employment and 50% of which shall vest on the first anniversary of his appointment, provided Dr. Barry is still serving as a director on such date.


Item 8.01 Other Events.


On September 21, 2021, the Company issued a press release announcing the appointment of Dr. Barry to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. 


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit Number





Press Release, dated September 21, 2021 (furnished herewith pursuant to Item 8.01)



Cover Page Interactive Data File (formatted as Inline XBRL)








Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





Date: September 22, 2021

By:  /s/ Kenneth L. Londoner                

Name: Kenneth L. Londoner 

Title: Executive Chairman




false 0001530766 0001530766 2021-09-20 2021-09-20